Merck (MRK) is among those interested in Inhibrx's (INBX) experimental cancer drug, Reuters reports citing source

This development indicates that Merck's interest in Inhibrx's experimental cancer drug could lead to potential strategic collaboration or acquisition, which may enhance Merck's oncology portfolio. Such moves can signal confidence in Inhibrx's technology and could impact valuations for both companies, as well as spark interest across the pharmaceutical sector in related assets.